286 related articles for article (PubMed ID: 20614162)
1. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
Servida F; Lecis D; Scavullo C; Drago C; Seneci P; Carlo-Stella C; Manzoni L; Polli E; Lambertenghi Deliliers G; Delia D; Onida F
Invest New Drugs; 2011 Dec; 29(6):1264-75. PubMed ID: 20614162
[TBL] [Abstract][Full Text] [Related]
2. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
Bockbrader KM; Tan M; Sun Y
Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
[TBL] [Abstract][Full Text] [Related]
3. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; Kashkar H; Walczak H; Delia D
Br J Cancer; 2010 Jun; 102(12):1707-16. PubMed ID: 20461078
[TBL] [Abstract][Full Text] [Related]
4. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
[TBL] [Abstract][Full Text] [Related]
5. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
6. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
7. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis.
Guo F; Nimmanapalli R; Paranawithana S; Wittman S; Griffin D; Bali P; O'Bryan E; Fumero C; Wang HG; Bhalla K
Blood; 2002 May; 99(9):3419-26. PubMed ID: 11964312
[TBL] [Abstract][Full Text] [Related]
8. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells.
Fandy TE; Shankar S; Srivastava RK
Mol Cancer; 2008 Jun; 7():60. PubMed ID: 18590557
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
[TBL] [Abstract][Full Text] [Related]
10. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
[TBL] [Abstract][Full Text] [Related]
12. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells.
Roa WH; Chen H; Fulton D; Gulavita S; Shaw A; Th'ng J; Farr-Jones M; Moore R; Petruk K
Clin Invest Med; 2003 Oct; 26(5):231-42. PubMed ID: 14596484
[TBL] [Abstract][Full Text] [Related]
13. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
[TBL] [Abstract][Full Text] [Related]
14. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
Sun H; Lu J; Liu L; Yang CY; Wang S
ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Respiration and Mitochondrial Dynamics by SMAC-Mimetics for Combination Therapy in Chemoresistant Cancer.
Hagenbuchner J; Oberacher H; Arnhard K; Kiechl-Kohlendorfer U; Ausserlechner MJ
Theranostics; 2019; 9(17):4909-4922. PubMed ID: 31410190
[TBL] [Abstract][Full Text] [Related]
16. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
Greer RM; Peyton M; Larsen JE; Girard L; Xie Y; Gazdar AF; Harran P; Wang L; Brekken RA; Wang X; Minna JD
Cancer Res; 2011 Dec; 71(24):7640-8. PubMed ID: 22049529
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
[TBL] [Abstract][Full Text] [Related]
18. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells.
Zhang S; Li G; Zhao Y; Liu G; Wang Y; Ma X; Li D; Wu Y; Lu J
PLoS One; 2012; 7(12):e51461. PubMed ID: 23240027
[TBL] [Abstract][Full Text] [Related]
19. Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.
Mao HL; Liu PS; Zheng JF; Zhang PH; Zhou LG; Xin G; Liu C
Pharmacol Res; 2007 Dec; 56(6):483-92. PubMed ID: 18029193
[TBL] [Abstract][Full Text] [Related]
20. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
